Drug Trial Radar · NCT04487236
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Oct 15, 2020
Primary completion
Apr 16, 2024
Study completion Apr 16, 2025
Sponsor
- Lead sponsor
- Suzhou Zanrong Pharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors. The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).
Conditions
- Advanced Solid Tumors
- HER2-positive Breast Cancer
Interventions
ZN-A-1041 50mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 100mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 200mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 400mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 600mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 800mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 1000mg BIDDrug
Orally 21days for one cycle
ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleDrug
ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleDrug
ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleDrug
ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First CycleDrug
Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1aTime frame: 23days
- The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1bTime frame: 21days
- The safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1cTime frame: through study completion, an average of 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer hospital Chinese academy of medical sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.